Brochure
More information from http://www.researchandmarkets.com/reports/2892292/

Hodgkin Lymphoma - Pipeline Review, H2 2014
Description:

Hodgkin Lymphoma - Pipeline Review, H2 2014
Summary
This, ‘Hodgkin Lymphoma - Pipeline Review, H2 2014’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin
Lymphoma and special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in
-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description,
MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hodgkin
Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hodgkin Lymphoma Overview
Therapeutics Development
Pipeline Products for Hodgkin Lymphoma - Overview
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis
Hodgkin Lymphoma - Therapeutics under Development by Companies
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Hodgkin Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hodgkin Lymphoma - Products under Development by Companies
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Seattle Genetics, Inc.
Merck & Co., Inc.
Gamida Cell Ltd.
Millennium Pharmaceuticals, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Sigma-Tau S.p.A.
Incyte Corporation
4SC AG
Dynavax Technologies Corporation
Spectrum Pharmaceuticals, Inc.
Affimed Therapeutics AG
Actinium Pharmaceuticals, Inc.
Philogen S.p.A.
Constellation Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc.
Rhizen Pharmaceuticals SA
Immune Pharmaceuticals, Inc.
Hodgkin Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles procarbazine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress

StemEx - Drug Profile
Product Description
Mechanism of Action
R&D Progress brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress entinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress ixazomib citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress resminostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFM-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress radretumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iomab-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress ricolinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferritarg - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-40346527 - Drug Profile
Product Description
Mechanism of Action

R&D Progress
Minor Histocompatibility Antigen - Drug Profile
Product Description
Mechanism of Action
R&D Progress pevonedistat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDX-1401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress vinorelbine tartrate liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSC-678515 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Inhibit CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 3 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP-400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP-776 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-047986 - Drug Profile
Product Description

Mechanism of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit CD47 for Metastatic Solid Tumors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferritizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hodgkin Lymphoma - Recent Pipeline Updates
Hodgkin Lymphoma - Dormant Projects
Hodgkin Lymphoma - Discontinued Products
Hodgkin Lymphoma - Product Development Milestones
Featured News & Press Releases
May 14, 2014: Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough
Therapy Designation for Hodgkin Lymphoma
Apr 10, 2014: Affimed Highlights Further Data on AFM13, a Bispecific CD30/CD16A TandAb in Development to Treat Hodgkin Lymphoma, at the 2014 AACR Annual Meeting
Apr 07, 2014: TG Therapeutics Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014
Feb 27, 2014: Seattle Genetics Highlights ADCETRIS Clinical Data at the 2014 Bone Marrow Transplant
Tandem Meetings
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or
Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th
American Society of Hematology Meeting
Oct 11, 2013: Seattle Genetics Highlights ADCETRIS (Brentuximab Vedotin) Clinical Data in the Frontline
Setting at the International Symposium on Hodgkin Lymphoma
Sep 16, 2013: Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a
Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients
Jun 24, 2013: Affimed Reports Phase I Clinical Data For Its Immunotherapy AFM13 In Relapsing/Refractory
Hodgkin Lymphoma Patients
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across
Broad Range Of Blood Cancers At 12th ICML
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hodgkin Lymphoma, H2 2014
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014

Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Comparative Analysis by Unknown Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014
Hodgkin Lymphoma - Pipeline by Johnson & Johnson., H2 2014
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2014
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2014
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014
Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2014
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2014
Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2014
Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2014
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2014
Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014
Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2014
Hodgkin Lymphoma - Pipeline by Immune Pharmaceuticals, Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014
Hodgkin Lymphoma - Dormant Projects, H2 2014
Hodgkin Lymphoma - Discontinued Products, H2 2014
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H2 2014
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2892292/
Order by Fax - using the form below

Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:

Hodgkin Lymphoma - Pipeline Review, H2 2014

Web Address:

http://www.researchandmarkets.com/reports/2892292/

Office Code:

SCJNU4HI

Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:

USD 2000

Electronic (PDF) Site License:

USD 4000

Electronic (PDF) Enterprisewide:

USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:

Mr

Mrs

Dr

Miss
Last Name:

Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Ms

Prof

Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:

You will receive an email with a link to a secure webpage to enter your credit card details.

Pay by check:

Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

Pay by wire transfer:

Please transfer funds to:
Account number

833 130 83

Sort code

98-53-30

Swift code

ULSBIE2D

IBAN number

IE78ULSB98533083313083

Bank Address

Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World